Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588749 | 0.83 | KDM1A (0.42) | ALDH1A1SMN1; SMN2USP2TSHR | |
| SCHEMBL14381563 | 0.80 | HRH3 (0.39) | KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14997963 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1GLAKDM4E | |
| SCHEMBL13588746 | 0.80 | PAOX (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4974769 | 0.78 | MEN1 (0.51) | MEN1KMT2AALDH1A1GLASMN1; SMN2 | |
| SCHEMBL28572354 | 0.77 | MEN1 (0.55) | MEN1KMT2AALDH1A1GLASMN1; SMN2 | |
| SCHEMBL13588755 | 0.77 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18705120 | 0.77 | DAO (0.41) | KMT2AALDH1A1KDM4E | |
| SCHEMBL21939494 | 0.77 | MEN1 (0.44) | MEN1KMT2AALDH1A1GLASMN1; SMN2 | |
| SCHEMBL13588739 | 0.74 | KCNA3 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885ALDH1A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.